Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Emphysema Treated with Minimally Invasive Stents

By HospiMedica International staff writers
Posted on 05 Jun 2012
A new treatment offers a minimally invasive alternative to lung volume-reduction surgery in a broad range of emphysema patients. More...


The RePneu Lung Volume Reduction Coil (LVRC) system is intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue, restore elastic recoil, and adjust lung compliance. The RePneu LVRC is preformed into a coil shape, but is delivered to the lung in a straight configuration, through a bronchoscope. When the coil is deployed into the lung, it recovers to its original coil shape, gathering and compressing diseased tissue and allowing the healthy tissue to function better. The procedure is performed under conscious sedation or general anesthesia, and does not require any surgical incision.

The system has proven effective in patients with both heterogeneous and homogeneous disease, in both the upper and lower lobes, and works independently of collateral ventilation. The safety profile of the RePneu LVRC System is comparable to that of a simple bronchoscopy procedure, with the majority of adverse results occurring, and resolving, within 30 days of treatment. Patients generally return home from the hospital the day after the treatment.

Extensive clinical studies in Europe have shown that the majority of subjects who underwent RePneu LVRC treatment experienced significant improvement in lung function, exercise capacity, and quality of life (QOL) with minimal risk; 74% of all clinical subjects maintained the improvement in exercise capacity at 12 months post-treatment, and 96% experienced significant improvement in quality of life. The RePneu LVRC System is a product of PneumRx (Mountain View, CA, USA), and has received the European Community CE Marking of approval.

“It has been so gratifying to see the benefits the RePneu LVRC treatment has brought to emphysema patients in Europe, and we are especially pleased to be able to bring these benefits to a greater number of patients suffering from this debilitating disease here in the United States,” said Erin McGurk, President and CEO of PneumRx, upon receiving US Food and Drug Administration (FDA) approval to commence a 30-site pivotal clinical trial to support a premarket application.

Related Links:
PneumRx


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Captivator EMR Device
Captivator Endoscopic Mucosal Resection Device
New
Mobile X-Ray Machine
MARS 15 / 30
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A specialized gas sensor embedded between the fabric layers of the FFP2-style face mask diagnoses CKD from a person’s breath (Photo courtesy of ACS Sensors 2025, DOI: 10.1021/acssensors.4c03227)

Specialized Face Mask with Gas Sensor Detects Chronic Kidney Disease

The kidneys play a crucial role in removing waste products generated by the body’s metabolic processes. However, in chronic kidney disease (CKD), these organs become damaged over time and lose their function,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.